Sanofi: positive data for Jevtana
(CercleFinance.com) - Sanofi announced on Monday that data published in the New England Journal of Medicine shows that for patients with metastatic cancer of the prostate gland, that is resistant to castration and whose disease has progressed within 12 months following the start of treatment with an agent targeting the androgen receiver (abiraterone or enzalutamide), the duration of survival without progression is significantly extended when they receive treatment with Jevtana and prednisone.
This is compared to treatment with abiraterone and prednisone or enzalutamide. "Overall survival (OS) with Jevtana was also significantly longer," Sanofi added.
Jevtana is a semi-synthetic taxane and a microtubular inhibitor. It is indicated in the treatment of adult patients with cancer of the metastatic prostate that is resistant to castration previously treated with a docetaxel-based treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.